Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
Study sponsor: Quoin Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-01-31Estimated
Enrollment · participants16Estimated
Source updated2026-09-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.